A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Trial details
- Registry ID
- NCT05178862
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Anidulafungin; Caspofungin; Micafungin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleNCT05178862 | SCYX | Phase 3 | Terminated | 2025-11-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |